Ticker

Deutsche Bank AG bought a new position in shares of ArriVent BioPharma, Inc. (NASDAQ: AVBP) in the undefined quarter, according to its most recent disclosure with the SEC. The institutional investor bought 39,180 shares of the company's stock, valued at approximately $1,361,000. Deutsche Bank AG owned 0.08% of ArriVent BioPharma at the end

The Firmonertinib readout moving to H2 2026 may signal slower event accumulation and longer progression-free survival. Firmonertinib remains the core value driver, with our base case assuming meaningful penetration across EGFR exon 20 insertion and PACC populations. Pipeline optionality is expanding, with ARR-217 entering Phase 1 and ARR-002 approaching first-patient dosing.

Shares of ArriVent BioPharma, Inc. (NASDAQ: AVBP - Get Free Report) have been assigned a consensus recommendation of "Moderate Buy" from the ten analysts that are presently covering the stock, Marketbeat reports. One equities research analyst has rated the stock with a sell rating, one has issued a hold rating and eight have issued a buy

Dimensional Fund Advisors LP lifted its stake in shares of ArriVent BioPharma, Inc. (NASDAQ: AVBP) by 758.2% in the first quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund owned 126,525 shares of the company's stock after acquiring an additional 111,782 shares during the

NEWTOWN SQUARE, Pa., Aug. 12, 2026 (GLOBE NEWSWIRE) -- ArriVent BioPharma, Inc. (Company or ArriVent) (Nasdaq: AVBP), a clinical-stage company dedicated to accelerating the global development of innovative biopharmaceutical therapeutics, today reported financial results for the second quarter ended June 30, 2026, and highlighted recent Company progress.